RxDoctor Payments Data

Chelsea Hartsook-Fields

Family · Rogersville, TNNPI 1366943383

Payments from drug & device makers

$575in general payments, 2019–2025

Across 36 payments — averaging $15.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$215
  • Novo Nordisk$75
  • Lilly USA, LLC$73
  • Esperion Therapeutics, Inc.$61
  • Vanda Pharmaceuticals Inc.$32
  • Axsome Therapeutics, Inc.$24
  • plus $96 from 6 others

What the payments were for

  • Food & beverage$55897%
  • Education$173%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$575 in reported general payments places this provider in the 50th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$822
Medicare patients
25
Services billed
74

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide78$89,927
MounjaroTirzepatide57$62,689
JardianceEmpagliflozin29$52,441
EliquisApixaban41$40,901
JanuviaSitagliptin Phosphate17$28,682
FarxigaDapagliflozin Propanediol25$28,049
VraylarCariprazine Hcl19$26,987
XareltoRivaroxaban23$18,625
QuliptaAtogepant11$13,740
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$13,556
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr28$13,326
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$10,631
LinzessLinaclotide15$8,372
Tresiba Flextouch U-100Insulin Degludec15$7,307
Lantus SolostarInsulin Glargine,hum.Rec.Anlog43$6,622

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$75$89,92778 claims
Lilly USA, LLCMounjaro$73$62,68957 claims
AbbVieVraylar, Qulipta, Linzess$215$49,09945 claims
PfizerEliquis$16$40,90141 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 6,706 family providers in Tennessee.

Other family in Rogersville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →